Updated guidance for PAT-DX1 phase 1 clinical study
Preclinical data supports synthetic lethality application
QUARTERLY ACTIVITIES REPORT & 4C
Patrys receives R&D Tax Incentive Refund
AGM Presentation
Patrys Appoints Dr Charmaine Gittleson as Chairman
Quarterly Activities Report and 4C
PAT-DX3 Crosses Blood Brain Barrier in Healthy Animals
PAT-DX1 Engineering Run Update
New Research Grant For Deoxymabs in Metastatic Breast Cancer
Previous
1
2
3
4
5
6
Next